{"id":4013,"date":"2025-06-27T12:29:23","date_gmt":"2025-06-27T09:29:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4013"},"modified":"2025-06-27T12:29:24","modified_gmt":"2025-06-27T09:29:24","slug":"entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies\/","title":{"rendered":"Entrada Therapeutics beginnt in Europa mit klinischen Studien f\u00fcr Exon 44- und Exon 45-Skipping-Therapien"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics hat in Europa offiziell klinische Studien f\u00fcr seine innovativen Exon-Skipping-Therapien gestartet, die auf Exon 44 und Exon 45 abzielen \u2013 ein bedeutender Meilenstein in der Behandlung der Duchenne-Muskeldystrophie (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Diese experimentellen Therapien zielen auf spezifische genetische Mutationen bei DMD-Patienten ab, um die Dystrophinproduktion wiederherzustellen und die klinischen Ergebnisse zu verbessern. Der Beginn dieser Studien unterstreicht das Engagement von Entrada f\u00fcr die Weiterentwicklung der Pr\u00e4zisionsgenetik und den weltweiten Zugang zu neuartigen Behandlungen f\u00fcr seltene neuromuskul\u00e4re Erkrankungen. \u2013 Weiterlesen: <a href=\"https:\/\/dmdwarrior.com\/de\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" rel=\"noreferrer noopener\">Was ist Exon-Skipping und wie funktioniert es?<\/a> \u2013<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Inhaltsverzeichnis<\/h2><nav><ul><li><a href=\"#entrada-exon-44-skipping-nct-07037862\">Entrada Exon 44 Skipping \u2013 NCT07037862 \u2013<\/a><\/li><li><a href=\"#entrada-exon-45-skipping-nct-07038824\">Entrada Exon 45 Skipping \u2013 NCT07038824 \u2013<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-44-skipping-nct-07037862\">Entrada Exon 44 Skipping \u2013 NCT07037862 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dies ist eine Studie zum Pr\u00fcfpr\u00e4parat ENTR-601-44 an Teilnehmern mit Duchenne-Muskeldystrophie (DMD), einer seltenen genetischen Erkrankung.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienbeginn (voraussichtlich)<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Prim\u00e4rer Abschluss (gesch\u00e4tzt)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienabschluss (gesch\u00e4tzt)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Anzahl der Teilnehmer (gesch\u00e4tzt)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Standorte<\/strong>: Belgien, Italien, Spanien, Vereinigtes K\u00f6nigreich.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienberechtigte Altersgruppen<\/strong>: 4 Jahre bis 20 Jahre (Kind, Erwachsener)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Wichtigste Einschluss- und Ausschlusskriterien. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07037862\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07037862<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-45-skipping-nct-07038824\">Entrada Exon 45 Skipping \u2013 NCT07038824 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dies ist eine Studie zum Pr\u00fcfpr\u00e4parat ENTR-601-45 an Teilnehmern mit Duchenne-Muskeldystrophie (DMD), einer seltenen genetischen Erkrankung.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienbeginn (voraussichtlich)<\/strong>: 2025-09-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Prim\u00e4rer Abschluss (gesch\u00e4tzt)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienabschluss (gesch\u00e4tzt)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Anzahl der Teilnehmer (gesch\u00e4tzt)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Standorte<\/strong>: Belgien, Italien, Niederlande, Spanien, Vereinigtes K\u00f6nigreich.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienberechtigte Altersgruppen<\/strong>: 4 Jahre bis 20 Jahre (Kind, Erwachsener)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Wichtigste Einschluss- und Ausschlusskriterien. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07038824\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07038824<\/a> \u2013<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/dmdwarrior.com\/de\/tag\/entrada-therapeutics\/\">Lesen Sie mehr \u00fcber Entrada Therapeutics<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45\u2014marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD). These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4021,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[242,233,234,84,246,319,178],"class_list":["post-4013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-europe","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=4013"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/4021"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=4013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=4013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}